Helix Acquisition Corp. HLXA
13.25 0.00 (+0.00%)
At closeApr 6, 2022, 12:00 AM EDT
10.71 Day range 15.11
6.64 52-week range 15.19
- Market cap
- 196.17M
- EPS (ttm)
- -0.307
- Shares out
- 11.93M
- P/E ratio
- -43.16
- Volume
- 554.07K
- Avg volume
- 92.83K
- Open
- 11.05
- Previous close
- 13.25
- Day's range
- 10.71 – 15.11
- 52-week range
- 6.64 – 15.19
No chart data for this range yet.
Key statistics
- Enterprise value
- 195.50M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 1.10M
- Total cash
- 666.79K
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 3.78%
- 50-day average
- 10.12
- 200-day average
- 10.00
Next earnings
Consensus EPS estimate 0.00.
About Helix Acquisition Corp.
As of April 5, 2022, Helix Acquisition Corp. was acquired by MoonLake Immunotherapeutics AG, in a reverse merger transaction. Helix Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. The company was founded in 2020 and is based in Boston, Massachusetts.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on HLXA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEN BIHUA X. | Chief Executive Officer | Purchase | Oct 21, 2020 | 0 |
| HELIX HOLDINGS L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 21, 2020 | 430,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.00% | 1,193,000 | 11.80M | Dec 30, 2021 |
| Adage Capital Partners GP L.L.C. | 8.48% | 1,011,589 | 10.00M | Dec 30, 2021 |
| Price (T.Rowe) Associates Inc | 6.26% | 746,862 | 7.39M | Dec 30, 2021 |
| Blackrock Inc. | 6.22% | 741,906 | 7.34M | Dec 30, 2021 |
| Citadel Advisors Llc | 5.75% | 685,937 | 6.78M | Dec 30, 2021 |
| 683 Capital Management LLC | 4.95% | 590,000 | 5.84M | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Advisor Biotechnology Fund | 10.00% | 1,193,000 | 11.77M | Jan 30, 2022 |
| Price (T.Rowe) Health Sciences Fund | 5.28% | 629,708 | 6.23M | Dec 30, 2021 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.90% | 226,542 | 2.25M | Nov 29, 2021 |
| BlackRock Health Sciences Trust II | 1.81% | 216,150 | 2.14M | Dec 30, 2021 |
| Tekla Healthcare Investors | 1.44% | 171,597 | 1.70M | Dec 30, 2021 |
| Tekla Life Sciences Investors | 0.66% | 78,403 | 775.40K | Dec 30, 2021 |